drugset / Trial / NCT02406222
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 2
Active not recruiting
124 enrolled
University of Leeds
Celgene Corporation · collabMyeloma UK · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is determining whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression free survival in patients with relapsed refractory myeloma (RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1 basis to receive CPD or Pd. Treatment will be continued until disease progression or unacceptable toxicity.
Timeline
- Start
- 2016-03
- Primary completion
- 2022-12
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 500 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |